Screener
EBIT at other companies
Other financials
Where this comes from
Calculated from Dyne Therapeutics, Inc.’s reported figures.
Plus components not separately reported this period.
The source filing: Dyne Therapeutics, Inc.’s 10-Q, filed May 11, 2026. Open the filing →
- Filed
- May 11, 2026, 7:25 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-215702
FAQ
- What is Dyne Therapeutics, Inc.'s EBIT?
- Dyne Therapeutics, Inc. (DYN) reported EBIT of -$125.28M in Q1 2026.
- How has Dyne Therapeutics, Inc.'s EBIT changed year-over-year?
- Dyne Therapeutics, Inc.'s EBIT decreased by 2.4% year-over-year, from -$122.37M to -$125.28M.
- What is the long-term trend for Dyne Therapeutics, Inc.'s EBIT?
- Over 4 years (2021 to 2025), Dyne Therapeutics, Inc.'s EBIT has grown at a 32.9% compound annual growth rate (CAGR), from -$150.03M to -$468.18M.
- What does EBIT mean?
- Earnings before interest and taxes — the profit from the business before financing cost and tax. Uses reported operating income where a company reports it; otherwise pre-tax income plus interest expense. Lets companies be compared on earning power independent of capital structure.
Ask your AI about Dyne Therapeutics, Inc.'s ebit.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude